Lundbeck encourages publication of data and results obtained from studies of its products and drug development candidates, and acknowledges a special obligation to publish data relating to patient safety.

The results of Lundbeck-sponsored controlled clinical pharmacology trials involving subjects suffering from the disorder under investigation, and all phase II, III and IV controlled clinical trials will be published in peer-reviewed journals or as abstracts, posters, or other presentations at scientific meetings, or posted on a publicly accessible clinical trial register. Publication activities will be undertaken in a responsible and ethical manner, to ensure that all relevant information is communicated clearly and in a timely way.

Confidentiality
Lundbeck respects the privacy of the relationship between patients and healthcare professionals and is committed to ensuring that the process of scientific publication does not breach patient confidentiality.